Added to YB: 2025-04-16
Pitch date: 2025-04-15
BIOA [bullish]
BioAge Labs, Inc.
Author Info
A team of 15-year-olds who share long, short, and quant trading ideas. Sign up for the newsletter.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases.
Market Cap
$131.9M
Pitch Price
N/A
Price Target
7.00 (+87%)
Dividend
N/A
Sector
Pharmaceuticals
Category
value
Show full summary:
Long BIOA: The biotech company whose cash reserves are more than double its market cap, which also possess a prized hidden asset which makes it a ripe acquisition target
BIOA: Long at 80% discount post-obesity drug failure. $150M mkt cap w/ $330M cash ($10/share) & NLRP3 asset (CNS-penetrant inflammation drug). Novartis deal: $20M upfront, $530M milestones. NLRP3 programs fetch $100Ms from pharma giants. IND filing 2H25; Phase 1 1H26. PT $7.
Read full article (10 min)